Search Result

Isoforms Recommended:	MHC II

Results for "

MHC-II

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MHC (5) Biochemical Assay Reagents (1) Caspase (1) Cathepsin (1) IFNAR (1) Interleukin Related (1) Lactate Dehydrogenase (1) LAG-3 (9) Reactive Oxygen Species (ROS) (1)
By Research Areas:	Cancer (9) Inflammation/Immunology (13) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Antibodies

Targets Recommended: MHC Photosystem II CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99736

Miptenalimab BI-754111	LAG-3	Cancer
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (K_D: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-112026

1-Adamantaneethanol	Biochemical Assay Reagents	Inflammation/Immunology
1-Adamantaneethanol, a hapten, influences peptide binding by MHC II .

HY-P99027

Ieramilimab LAG525; IMP701; Hu5A8	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .

HY-W016773

1,10-Decanediol	MHC	Metabolic Disease Inflammation/Immunology
1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatory T cells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism .

HY-157280

AdCaPy	MHC	Inflammation/Immunology
AdCaPy is an *MHC II* antigen loading catalyst that accelerates the loading of peptide antigens by MHC II. AdCaPy is a useful molecular tool for enhancing immune responses .

HY-157277

AdBeSA	Others	Cancer
AdBeSA is a hapten. AdBeSA can influence peptide binding by MHC II .

HY-P10835

LAG-3 cyclic peptide inhibitor C25	LAG-3	Cancer
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a K_d value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 ⁺ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .

HY-164308

SA-15-P	LAG-3	Inflammation/Immunology
SA-15-P inhibits *LAG-3/MHCII* and LAG-3/FGL1 interactions with IC₅₀ values of 4.21 and 6.52 μM respectively. LAG-3/MHCII interaction is a target for immunotherapies .

HY-157171

Ac-YR-NH2	MHC	Inflammation/Immunology
Ac-YR-NH2 is a small molecule modulator of MHC class II antigen presentation. Ac-YR-NH2 can influence peptide binding by MHC II to influence immune response .

HY-157269

J10-1	Others	Inflammation/Immunology
J10-1 is a hapten. J10-1 promotes peptide exchange of all DR alleles (DR1, DR2, DR4 (DRB10401)) and promotes peptide binding to MHC II*, which can be used in the study of immune regulation .

HY-P99922

Encelimab	LAG-3	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .

HY-176814

LAG-3-IN-1	LAG-3	Cancer
LAG-3-IN-1 (Compound 11) is a LAG-3 inhibitor with a K_D of 0.41  μM. LAG-3-IN-1 disrupts the LAG-3/MHCII interaction, enhances IFN-γ secretion and promotes tumor cell killing in cocultures of PBMCs and cancer cells. LAG-3-IN-1 can be used for cancers like ovarian cancer, colon adenocarcinoma and melanoma research .

HY-P10382

M133 peptide	MHC	Inflammation/Immunology
M133 peptide is a coronavirus-specific CD4 T cell epitope. M133 peptide is immunodominant in mice infected with the neurotropic coronavirus (the JHM strain of mouse hepatitis virus). M133 peptide forms a complex with MHC II molecules, which is recognized by specific TCRs, thereby activating CD4 T cells .

HY-P99156

Relatlimab 3 Publications Verification BMS-986016	LAG-3	Cancer
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC₅₀ value of 0.67 nM and LAG-3/FGL1 interaction with an IC₅₀ value of 0.019 nM. Relatlimab can be used in research of cancer .

HY-P990839

Anti-IFNγ Antibody (B133.5)	IFNAR	Inflammation/Immunology
Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody inhibitor, targeting to human IFNγ. Anti-IFNγ Antibody (B133.5) can neutralize human IFNγ (interferon gamma). Anti-IFNγ Antibody (B133.5) can be used for the research of immunology .

HY-P5898

Z-Val-Val-Nle-diazomethylketone Z-Val-Val-Nle-CHN2	Cathepsin MHC	Inflammation/Immunology
Z-Val-Val-Nle-diazomethylketone is a cathepsin S (CATS) inhibitor. Z-Val-Val-Nle-diazomethylketone significantly inhibits the IFNg-induced upregulation of the *MHCII* molecules HLA-DR and Ii-p33/35 with an increase of Ii-p10 protein level. Z-Val-Val-Nle-diazomethylketone can be used for dermatological diseases like psoriasis, atopic dermatitis and actinic keratosis research .

HY-157992

LM-021	Interleukin Related Caspase Lactate Dehydrogenase Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
LM-021 is a coumarin-chalcone derivative with anti-aggregatory, antioxidant, neuroprotective and anti-inflammatory properties which suppresses nitric oxide (NO), IL-1β, IL-6, TNF-α production, CD68 antigen (CD68) and histocompatibility-2 (MHCII) expression. LM-021 also attenuates the increase of caspase 1 activity, lactate dehydrogenase release and ROS level. LM-021 can be used for neurological research .

HY-P99141

Anti-Mouse LAG-3 Antibody (C9B7W)	LAG-3	Inflammation/Immunology Cancer
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 ⁺ T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .

Cat. No.	Product Name	Target	Research Area

HY-P10441A

S-palm P0(180–199) TFA 1 Publications Verification	Peptides	Inflammation/Immunology
S-palm P0(180–199) (TFA) is a peptide that enhances MHC II-restricted responses. S-palm P0(180–199) (TFA) can be used to establish models of chronic inflammatory demyelinating polyneuropathy (CIDP) and chronic experimental autoimmune neuritis (c-EAN). S-palm P0(180–199) (TFA) is used for studying autoimmune-mediated neuroinflammatory diseases .

HY-P5412

LLO (190-201) Listeriolysin O 190 peptide	Peptides	Others
LLO (190-201) (Listeriolysin O 190 peptide) is a biological active peptide. (This peptide is a major histocompatibility complex class II (MHC-II)-restricted peptide, LLO190 (NEKYAQAYPNVS), from the listeriolysin O protein of Listeria monocytogenes, which generates an LLO190-specific Th response. This peptide subsequently challenge recombinant L. monocytogenes expressing the MHC-I-restricted epitope of ovalbumin (Ova257, SIINFEKL).)

HY-P10835

LAG-3 cyclic peptide inhibitor C25	LAG-3	Cancer
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a K_d value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 ⁺ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .

HY-P10382

M133 peptide	MHC	Inflammation/Immunology
M133 peptide is a coronavirus-specific CD4 T cell epitope. M133 peptide is immunodominant in mice infected with the neurotropic coronavirus (the JHM strain of mouse hepatitis virus). M133 peptide forms a complex with MHC II molecules, which is recognized by specific TCRs, thereby activating CD4 T cells .

HY-P5898

Z-Val-Val-Nle-diazomethylketone Z-Val-Val-Nle-CHN2	Cathepsin MHC	Inflammation/Immunology
Z-Val-Val-Nle-diazomethylketone is a cathepsin S (CATS) inhibitor. Z-Val-Val-Nle-diazomethylketone significantly inhibits the IFNg-induced upregulation of the *MHCII* molecules HLA-DR and Ii-p33/35 with an increase of Ii-p10 protein level. Z-Val-Val-Nle-diazomethylketone can be used for dermatological diseases like psoriasis, atopic dermatitis and actinic keratosis research .

Cat. No.	Product Name	Target	Research Area

HY-P99736

Miptenalimab BI-754111	LAG-3	Cancer
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (K_D: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P99027

Ieramilimab LAG525; IMP701; Hu5A8	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .

HY-P99922

Encelimab	LAG-3	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .

HY-P99156

Relatlimab 3 Publications Verification BMS-986016	LAG-3	Cancer
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC₅₀ value of 0.67 nM and LAG-3/FGL1 interaction with an IC₅₀ value of 0.019 nM. Relatlimab can be used in research of cancer .

HY-P990839

Anti-IFNγ Antibody (B133.5)	IFNAR	Inflammation/Immunology
Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody inhibitor, targeting to human IFNγ. Anti-IFNγ Antibody (B133.5) can neutralize human IFNγ (interferon gamma). Anti-IFNγ Antibody (B133.5) can be used for the research of immunology .

HY-P99141

Anti-Mouse LAG-3 Antibody (C9B7W)	LAG-3	Inflammation/Immunology Cancer
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 ⁺ T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P85015

	HLA-DR Antibody (YA4707) DASS-397D15.1 antibody; DR alpha chain antibody; DR alpha chain precursor antibody; DRA_HUMAN antibody; DRB1 antibody; DRB4 antibody; FLJ51114 antibody; Histocompatibility antigen HLA DR alpha antibody; Histocompatibility antigen HLA-DR alpha antibody; HLA class II histocompatibility antigen antibody; HLA class II histocompatibility antigen DR alpha chain antibody; HLA DR1B antibody; HLA DR3B antibody; HLA DRA antibody; HLA DRA1 antibody; HLA DRB1 antibody; HLA DRB3 antibody; HLA DRB4 antibody; HLA DRB5 antibody; HLA-DR histocompatibility type antibody; HLA-DRA antibody; HLADR4B antibody; HLADRA1 antibody; HLADRB antibody; Major histocompatibility complex class II DR alpha antibody; Major histocompatibility complex class II DR beta 1 antibody; Major histocompatibility complex class II DR beta 3 antibody; Major histocompatibility complex class II DR beta 4 antibody; Major histocompatibility complex class II DR beta 5 antibody; MGC117330 antibody; MHC cell surface glycoprotein antibody; MHC class II antigen DRA antibody; MHC II antibody; MLRW antibody; OTTHUMP00000029406 antibody; OTTHUMP00000029407 antibody; HLA-DRA nanobody;	ELISA	Human
	HLA-DR Antibody (YA4707) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to HLA-DR.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: